Verrica Pharmaceuticals Inc.
corporate_fare Company Profile
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for VRCA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for VRCA spans 10-Q, 8-K, 4, DEF 14A.
Recent high-impact activity:
- Verrica 10-Q: Record YCANTH Revenue, but Going-Concern Warning as Cash Falls to $14.4M
- Verrica Q3 Revenue Up 58% to $5.7M; Runway Extended Into Q4 2027
- YCANTH Revenue Jumps 57.9% to $5.7M as Verrica Secures $27.5M Growth Capital
- Verrica Completes Enrollment in Pivotal COVE-2 Warts Trial; Topline Data Due Q1 2027
- CEO Jayson Rieger Buys $125,750 of Verrica Stock in Open Market
Financial Snapshot
Short Interest & Short Volume
4.58 days to coverFINRA reported short interest of 244,405 shares in VRCA as of the October 30, 2026 settlement, a 26.9% increase from the prior period — about 4.6 days to cover at its recent average daily volume. On November 20, 2026, 38.2% of VRCA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.